Table 1. Sample sizes by participating study site in discovery and replication phases.
| Phase | Study | Ancestry | No. of controls | No. of cases | No. of recurrent |
|---|---|---|---|---|---|
| Discovery | Bonn Mannheim | EUR | 1072 (48.3) | 588 (64.1) | 408 (66.7) |
| GenRED1 | EUR | 1097 (42.7) | 1020 (70.8) | 1020 (70.8) | |
| GSK MPIP | EUR | 859 (67.6) | 861 (67.4) | 831 (67.3) | |
| MPIP MARS 650 | EUR | 539 (54.5) | 373 (55.2) | 128 (59.4) | |
| NTR/NESDA | EUR | 1727 (62.0) | 1685 (69.2) | 834 (71.2) | |
| QIMR I317 | EUR | 960 (55.2) | 1017 (61.0) | 524 (65.6) | |
| QIMR I610 | EUR | 748 (61.9) | 433 (72.3) | 250 (72.4) | |
| RADIANT | EUR | 1549 (54.2) | 1903 (70.5) | 1441 (70.8) | |
| RADIANT—Germany | EUR | 217 (53.9) | 327 (65.7) | 254 (70.5) | |
| STAR*D | EUR | 447 (43.8) | 1240 (58.6) | 912 (59.1) | |
| CONVERGEa | EAS | 5220 | 5282 | 5282 | |
| Replicationb | Edinburgh | EUR | 285 (48.8) | 372 (59.4) | — |
| DepGenesNetwork | EUR | 470 (62.6) | 471 (77.5) | 471 (77.5) | |
| GenRED2 | EUR | 474 (48.9) | 830 (82.8) | 830 (82.8) | |
| Harvard i2b2 | EUR | 1067 (50.1) | 806 (66.9) | 806 (66.9) | |
| Janssen | EUR | 1380 (60.5) | 466 (68.2) | 466 (68.2) | |
| QIMR COEX | EUR | 526 (57.6) | 565 (71.5) | — | |
| RADIANT—Irish cases | EUR | 340 (52.4) | 109 (82.6) | 109 (82.6) | |
| RADIANT—US cases | EUR | 378 (51.9) | 223 (78.5) | 223 (78.5) | |
| RADIANT—Denmark cases | EUR | 516 (40.7) | 133 (69.9) | 133 (69.9) | |
| SHIP-LEGEND | EUR | 1087 (44.0) | 366 (67.8) | — | |
| SHIP-TREND-0 | EUR | 484 (44.6) | 163 (71.8) | — | |
| Totals | Discovery | 14 435 (71.3) | 14 729 (78.4) | 11 884 (82.2) | |
| Replication | 7007 (51.6) | 4504 (72.3) | 2572 (75.8) |
Abbreviations: EAS, East Asian; EUR, European.
Numbers of female subjects are displayed parenthetically.
a
All cases and controls were female
.
b
See note in Materials and methods section.